GlassScriptPhysician profile
James Torrico
NPI 1720331341
$16,840.34
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,014 · 2022: $3,541 · 2023: $4,479 · 2024: $5,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,433 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,565 · Travel and Lodging: $1,175 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,433.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,565.00 |
| Travel and Lodging | $1,175.15 |
| Education | $111.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,301.18 | 2021-2024 | |
| Madrigal Pharmaceuticals | $4,093.66 | 2024 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $1,106.20 | 2021-2024 | Stelara, Simponi, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $902.56 | 2021-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $736.96 | 2021-2024 | Xifaxan |
| Janssen Scientific Affairs, LLC | $709.62 | 2021-2024 | Stelara, Tremfya |
| Celgene Corporation | $654.89 | 2021-2024 | Zeposia |
| Pfizer INC. | $553.86 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $418.69 | 2021-2023 | |
| Daiichi Sankyo INC. | $410.93 | 2021-2023 | Injectafer |
| Redhill Biopharma INC. | $245.99 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Gilead Sciences, INC. | $243.85 | 2021-2024 | |
| Genzyme Corporation | $172.82 | 2023 | |
| Ironwood Pharmaceuticals, INC | $161.10 | 2021-2023 | Linzess |
| Qol Medical, LLC | $147.49 | 2022-2023 | Sucraid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $127.82 | 2022-2023 | Dupixent |
| Exelixis INC. | $124.98 | 2023 | Cabometyx |
| Axonics, INC. | $107.66 | 2022 | |
| Intercept Pharmaceuticals, INC. | $107.29 | 2021-2024 | Ocaliva |
| Vivus LLC | $74.61 | 2023-2024 | Qsymia |
| Regeneron Pharmaceuticals, INC. | $73.47 | 2023 | |
| Fresenius Kabi USA, LLC | $70.00 | 2023-2024 | Idacio |
| Nestle Healthcare Nutrition INC. | $68.58 | 2021 | |
| Lilly USA, LLC | $43.99 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $43.52 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $42.21 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $21.05 | 2023 | Voquezna |
| Biocon Biologics INC | $20.53 | 2024 | Hulio |
| Astrazeneca Pharmaceuticals LP | $19.09 | 2023 | Andexxa |
| Mylan Institutional INC. | $18.08 | 2023 | Hulio |
| Alexion Pharmaceuticals, INC. | $17.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Torrico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.